Patent SG-11201809082W-A (SG)
Title: Nlrp3 modulators
Inventor: GLICK GARY
IPC: C07D519/00
Filed: 2017-04-19
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 26 October 2017 (26.10.2017) WIPO I PCT omit VIII Hot o 110 110 W IIII i11110 ow (10) International Publication Number WO 2017/184746 Al (51) International Patent Classification: CO7D 471/04 (2006.01) A61P 35/00 (2006.01) CO7D 519/00 (2006.01) A61P 37/00 (2006.01) A61K 31/437 (2006.01) (21) International Application Number: PCT/US2017/028384 (22) International Filing Date: 19 April 2017 (19.04.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/324,626 19 April 2016 (19.04.2016) US 62/460,519 17 February 2017 (17.02.2017) US (71) Applicant: IFM THERAPEUTICS, INC [US/US]; 855 Boylston Street, Suite 1103, Boston, Massachusetts 02116 (US). (72) Inventors: GLICK, Gary; 1663 Snowberry Ridge Rd., Ann Arbor, Michigan 48103 (US). GHOSH, Shomir; 134 Sewall Avenue, Unit C, Brookline, Massachusetts 02446 (US). ROUSH, William R.; 1013 Town Hall Avenue, Jupiter, Florida 33458 (US). OLHAVA, Edward James; 11 Scarsdale Rd, Newton, Massachusetts 02460 (US). TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: — with international search report (Art. 21(3)) - before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) 1-1 71 N - 71 00 - 1-1 N 1-1 O (74) Agent: KENDALL, John T. et al.; Fish & Richardson P.C., P.O. Box 1022, Minneapolis, Minnesota 55440-1022 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (54) Title: NLRP3 MODULATORS (57) : This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/ or cocrystal, and/or drug combination of the compound) that modulate (e.g., agonizes or partially agonizes) NLRP3 that are useful, e.g., for treating a condition, disease or disorder in which a decrease in NLRP3 activity (e.g., a condition, disease or disorder associated with repressed or impaired NLRP3 signaling) contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions as well as other methods of using and making the same.